Radiopharm Theranostics Signs Supply Deal with Siemens
Ticker: RADX · Form: 6-K · Filed: 2026-04-07T08:00:02-04:00
Sentiment: bullish
Topics: supply-agreement, clinical-trial, radiopharmaceuticals
TL;DR
Radiopharm inks Siemens deal for RAD101 – big step for their cancer drug!
AI Summary
Radiopharm Theranostics Ltd. announced on April 7, 2026, a clinical supply agreement with Siemens for its RAD101 product. This agreement is a significant step in the development and potential commercialization of Radiopharm's radiopharmaceutical assets.
Why It Matters
This collaboration with a major player like Siemens could accelerate the clinical trials and market access for Radiopharm's RAD101, potentially impacting the treatment landscape for certain diseases.
Risk Assessment
Risk Level: medium — The success of this agreement is contingent on the clinical trial outcomes of RAD101 and Siemens' continued commitment.
Key Players & Entities
- Radiopharm Theranostics Ltd (company) — Filer of the 6-K report
- Siemens (company) — Party to the clinical supply agreement
- RAD101 (product) — Product subject to the clinical supply agreement
FAQ
What is the specific nature of the clinical supply agreement between Radiopharm Theranostics and Siemens?
The filing indicates a clinical supply agreement for RAD101, but the specific terms and scope are detailed in Exhibit 99.1, which is not fully provided in this summary.
When was this clinical supply agreement announced?
The agreement was announced on April 7, 2026, as indicated by the filing date of the 6-K report.
What is RAD101?
RAD101 is a product developed by Radiopharm Theranostics Ltd. that is the subject of the clinical supply agreement with Siemens.
What is the significance of Siemens' involvement?
Siemens is a major company, and their involvement suggests a potential for broader clinical development and commercialization of Radiopharm's RAD101 product.
Where is Radiopharm Theranostics Ltd. based?
Radiopharm Theranostics Ltd. is based in Carlton, Victoria, Australia, with its mailing and business addresses listed as LEVEL 3, 62 LYGON STREET CARLTON VIC Australia 3053.
Filing Stats: 322 words · 1 min read · ~1 pages · Grade level 19 · Accepted 2026-04-07 08:00:02
Filing Documents
- ea0285363-6k_radiopharm.htm (6-K) — 12KB
- ea028536301ex99-1.htm (EX-99.1) — 11KB
- ea028536301_ex99-1img1.jpg (GRAPHIC) — 11KB
- 0001213900-26-040690.txt ( ) — 39KB
From the Filing
OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2026 Commission File Number: 001-41621 RADIOPHARM THERANOSTICS LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes No If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- RADIOPHARM THERANOSTICS LIMITED EXPLANATORY NOTE Radiopharm Theranostics Limited (the “Company”) published one announcement (the “Public Notice”) to the Australian Securities Exchange on April 7, 2026 titled: “RAD and Siemens Sign Clinical Supply Agreement for RAD101 ” A copy of the Public Notice is attached as an exhibit to this report on Form 6-K. This report on Form 6-K (including the exhibit hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing. 1 EXHIBITS Exhibit Number Description 99.1 RAD and Siemens Sign Clinical Supply Agreement for RAD101 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. RADIOPHARM THERANOSTICS LIMITED Date: April 7, 2026 By: /s/ Phillip Hains Phillip Hains Company Secretary 3